Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NUVB
SELLNuvation Bio Inc. · Healthcare · United States · $2.2B · Avg Vol: $52M/d
COMPANY DESCRIPTION
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing a proprietary pipeline of novel, targeted oncology therapies to address significant unmet needs in cancer care. The company's competitive moat is built on its advanced drug discovery engine, which targets key oncogenic drivers and resistance mechanisms, highlighted by its lead candidate taletrectinib, a potential best-in-class ROS1 inhibitor. Led by an experienced management team with a track record of successful oncology drug development, Nuvation Bio is well-positioned to advance its deep pipeline of small molecule candidates.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.9M | 62.9M | 699.0% | 143.0M | 202.9M | 289.9M | 114.7% |
| EPS | -0.48 | -0.35 | -2.11 | -0.60 | — | -0.46 | -0.28 | -0.06 | — |
| Shares | 218.6M | 219.0M | 337.8M | 346.5M | +58.5% | 347.2M | — | — | — |
| Debt | 4.3M | 4.0M | 8.9M | 57.4M | 137.9% | 217.0M | — | — | — |
| Equity | 655.1M | 605.1M | 463.8M | 305.7M | -22.4% | — | — | — | — |
| Op CF | -96.1M | -68.0M | -130.4M | -173.4M | — | -125.7M | — | — | — |
| Inv CF | 63.5M | 8.9M | 122.7M | 99.5M | — | — | — | — | — |
| Fin CF | 1.3M | 0.6M | 0.3M | 202.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NUVB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NUVB | Nuvation Bio Inc.(you) | $2.2B | 26 | SELL |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.6B | 27 | SELL |
| KOD | Kodiak Sciences Inc. | $2.6B | 26 | SELL |
| SION | Sionna Therapeutics, Inc. | $2.1B | 28 | SELL |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.6B | 26 | SELL |
| STOK | Stoke Therapeutics, Inc. | $1.8B | 26 | SELL |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.9B | 25 | SELL |
| PVLA | Palvella Therapeutics, Inc. | $2.0B | 28 | SELL |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | 29 | SELL |
| NKTR | Nektar Therapeutics | $2.4B | 21 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%